ScreenerHero

ACETAdicet Bio, Inc.

NAS · US · Healthcare · Biotechnology · adicetbio.com
9.190USD-3.16%Mkt Cap: 86.03M $P/E: —

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prul…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap86.03M $
Enterprise Value-4.37M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-116.80M $
Revenue/Share—
Last Price9.190 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0070021086
Valuation
P/E (Trailing)—
P/E (Forward)-2.37
PEG—
EV/EBITDA0.04
EV/Revenue—
P/S—
P/B0.84
EPS (TTM)-10.42
EPS (Forward)-3.95
52W Range
6.01028% of range17.44
52W High17.44 USD
52W Low6.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.36%
ROA-60.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.25M $
CapEx (TTM)1.74M $
FCF Margin—
FCF Yield-55.23%
Net Debt-105.34M $
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.09
Current Ratio6.71
Quick Ratio6.59
Book Value/Sh11.16 USD
Cash/Share10.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2020
Splits
Last Split1:16
Split DateDec 30, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.17 USD
Upside (mean)+260.9%
Target Range18.00 USD – 90.00 USD
$18.00+260.9% to mean$90.00
# Analysts6
Ownership
Shares Out.9.36M
Float7.44M
Insiders1.08%
Institutions64.91%
Short Interest
Short Ratio4.2d
Short % Float4.26%
Short % Out.4.24%
Shares Short397.05K
Short (prev mo.)505.58K
Technical
SMA 508.456 (+8.7%)
SMA 2008.155 (+12.7%)
Beta1.59
S&P 52W Chg18.16%
Avg Vol (30d)89.98K
Avg Vol (10d)72.53K
Technical Indicators
RSI (14)58.4
MACD0.1403
MACD Signal0.0799
MACD Hist.+0.0604
BB Upper9.622 USD
BB Middle8.582 USD
BB Lower7.542 USD
BB Width24.24%
ATR (14)0.5415 USD
Vol Ratio (20d)0.92x